Nano-formulations containing SBECD

Posted by

Various nano-formulations containing SBECD have been studied in order to utilize the inclusion complex forming (solubilizing, stabilizing) ability of this CD derivative in synergy with the benefits of the nanosized particles/droplets (1). Some examples are listed below:

Nanoparticles formed by chitosan and SBE-β-CD were thoroughly studied for various drugs, such as econazole nitrate and hydrocortisone (2,3). They were also used to formulate slow-release tablet of famotidine (4). Zhang et al. developed naringenin-loaded SBE-β- CD-chitosan nanoparticles for ocular administration (5). The results of in vivo studies in rabbits showed that naringenin bioavailability was significantly enhanced in aqueous humor in comparison to naringenin suspension. Chitosan/SBECD surface-adsorbed naringenin-loaded nanocapsules were found to enhance bacterial quorum quenching and showed anti-biofilm activities against Pseudomonas aeruginosa (6).

Nanoemulsions (nanodroplets) have similar advantages. Li et al. (7) found that the surfactant Kolliphor® HS 15 (HS 15) and SBECD had significant synergistic effects on solubilizing voriconazole, and a novel voriconazole complex delivery system (VRC-CD/HS 15) was established which had better physicochemical properties and similar antifungal effect compared to the marketed SBECD-enabled formulation of voriconazole. Nanoemulsion stabilized by various surfactants (Tween 80, poloxamer 407 and polyethylene glycol 400) were prepared to form carnosic acid/SBECD nanoparticles (>100 nm) to improve the solubility, circulation stability and brain bioavailability of carnosic acid (8).

References:

  1. Das O, Ghate VM, Lewis SA. (2019) Utility of Sulfobutyl Ether beta-Cyclodextrin Inclusion Complexes in Drug Delivery: A Review. Indian J Pharm Sci 81, 589-600. https://doi.org/10.36468/pharmaceutical-sciences.549
  2. Mahmoud AA, El-Feky GS, Kamel R, Awad GE. (2011) Chitosan/sulfobutylether-β-cyclodextrin nanoparticles as a potential approach for ocular drug delivery. Int J Pharm 413, 229-236. https://doi.org/10.1016/j.ijpharm.2011.04.031
  3. Fulop Z, Saokham P, Loftsson T. (2014) Sulfobutylether-beta-cyclodextrin/chitosan nano- and microparticles and their physicochemical characteristics. Int J Pharm 472, 282-287. https://doi.org/10.1016/j.ijpharm.2014.06.039
  4. Anraku M, Hiraga A, Iohara D, Pipkin JD, Uekama K, Hirayama F. (2015) Slow-release of famotidine from tablets consisting of chitosan/sulfobutyl ether β-cyclodextrin composites. Int J Pharm 487, 142-147. https://doi.org/10.1016/j.ijpharm.2015.04.022
  5. Zhang P, Liu X, Hu W, Bai Y, Zhang L. (2016) Preparation and evaluation of naringenin loaded sulfobutyl ether beta cyclodextrin chitosan nanoparticles for ocular delivery. Carbohydr Polym 149, 224-230. https://doi.org/10.1016/j.carbpol.2016.04.115
  6. Nguyen HT, Hensel A, Goycoolea FM. (2021) Chitosan/cyclodextrin surface-adsorbed naringenin-loaded nanocapsules enhance bacterial quorum quenching and anti-biofilm activities. Colloids and Surfaces B: Biointerfaces 112281. https://doi.org/10.1016/j.colsurfb.2021.112281.
  7. Li Y, Zhu C , Wu H , Pan H, Liu H. (2020) Kolliphor® HS 15-cyclodextrin Complex for the Delivery of Voriconazole: Preparation, Characterization, and Antifungal Activity, Current Drug Metabolism 21(5), 379-389. https://dx.doi.org/10.2174/1389200221666200520085915
  8. Mahmoud AA, El-Feky GS, Kamel R, Awad GE. (2011) Chitosan/sulfobutylether-β-cyclodextrin nanoparticles as a potential approach for ocular drug delivery. Int J Pharm 413, 229-236. https://doi.org/10.1016/j.ijpharm.2011.04.031
  9. Wang Y-B, Xiang L, Bing Y et al. (2022) Inhibition of the CEBPβ-NFκB interaction by nanocarrier-packaged Carnosic acid ameliorates glia-mediated neuroinflammation and improves cognitive function in an Alzheimer’s disease model. Cell Death Dis 13, 318. https://doi.org/10.1038/s41419-022-04765-1

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.